Provided by Tiger Trade Technology Pte. Ltd.

Artiva Biotherapeutics, Inc.

10.93
-0.2100-1.89%
Post-market: 10.930.00000.00%19:30 EDT
Volume:199.42K
Turnover:2.21M
Market Cap:534.32M
PE:-3.41
High:11.60
Open:11.26
Low:10.76
Close:11.14
52wk High:14.53
52wk Low:2.22
Shares:48.89M
Float Shares:19.90M
Volume Ratio:0.63
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2084
EPS(LYR):-3.4309
ROE:-36.58%
ROA:-22.34%
PB:1.54
PE(LYR):-3.19

Loading ...

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

TIPRANKS
·
May 08

Artiva Biotherapeutics prices USD 300 million follow-on equity offering at USD 11.52/share

Reuters
·
May 08

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
May 08

Artiva Biotherapeutics Inc - Prices Offering of 23.9 Mln Shares at $11.52 per Share and 2.2 Mln Pre-Funded Warrants at $11.5199 per Share

THOMSON REUTERS
·
May 08

BUZZ-Artiva jumps as cell therapy shows benefits in rheumatoid arthritis

Reuters
·
May 08

Artiva Biotherapeutics Inc - Suspends Offering of Common Stock Under Sales Agreement With Leerink Partners - SEC Filing

THOMSON REUTERS
·
May 08

Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate

Benzinga Earnings
·
May 08

Artiva Biotherapeutics Inc - Cash, Cash Equivalents and Investments $86.8 Mln as of March 31, 2026; Funds Operations Into Q2 2027

THOMSON REUTERS
·
May 08

Artiva Biotherapeutics Inc Qtrly EPS $-0.95

THOMSON REUTERS
·
May 08

Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
May 08

Artiva plans Phase 3 rheumatoid arthritis trial of AlloNK plus rituximab in 2026

Reuters
·
May 08

Artiva Biotherapeutics Inc - Initial Data Shows 71% Acr50 Response in Refractory Ra Patients at Six Months

THOMSON REUTERS
·
May 08

Artiva Announces Positive Initial Clinical Data With Allonk® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

THOMSON REUTERS
·
May 08

Artiva Biotherapeutics Inc - Registrational Trial Initiation Expected in H2 2026, Primary Data in H2 2028

THOMSON REUTERS
·
May 08

Artiva Biotherapeutics Inc - Allonk Shows Favorable Tolerability Profile With No Crs, Icans, or Discontinuations

THOMSON REUTERS
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Artiva Biotherapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Reuters
·
May 04

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Artiva Biotherapeutics, Inc. (ARTV) and Emergent Biosolutions (EBS)

TIPRANKS
·
May 04

Artiva Biotherapeutics Price Target Maintained With a $18.00/Share by Needham

Dow Jones
·
May 04

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
Apr 08